170504 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Quantifying Her2 protein for optimal cancer therapy
#302Methods of assessing cellular breast samples and compositions for use in practicing the same
#303Isoform specific soluble FMS-like tyrosine kinase (sFlt) binding agents and uses thereof
#304SRM/MRM assay for the fibroblast growth factor receptor 2 (FGFR2) protein
#305AGENTS, METHODS AND KITS FOR TREATING AND DETECTING DIABETIC NEPHROPATHY AND PROLIFERATIVE DISEASES AND METHODS FOR INHIBITING EXPRESSION OF TYPE IV COLLAGEN
#306DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#307USE OF NEUREGULIN-4 FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE AND NECROTIZING ENTEROCOLITIS
#308Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
#309Compositions and methods for growth factor modulation
#310Method for diagnosing and monitoring inflammatory disease progression
#311METHOD OF STUDYING REACTIONS BETWEEN TWO OR MORE MOLECULES IN A BIOLOGICAL SAMPLE
#312Modular point-of-care devices, systems, and uses thereof
#313Modular point-of-care devices, systems, and uses thereof
#314Modular point-of-care devices, systems, and uses thereof
#315Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof
#316CMET protein SRM/MRM assay
#317METHODS AND APPARATUS FOR CONDUCTING MULTIPLE MEASUREMENTS ON A SAMPLE
#318Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells
#319SOLUBLE VEGFR-1 VARIANTS AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS
#320Detection of ovarian cancer using antibody arrays
#321Methods of diagnosing, classifying and treating endometrial cancer and precancer
#322METHOD TO PREDICT OR DIAGNOSE A COLORECTAL CANCER
#323VIRUS-LIKE PARTICLE FOR USE IN IMMUNOASSAY, BLOCKING AGENT FOR USE IN THE IMMUNOASSAY, AND KIT COMPRISING THE VIRUS-LIKE PARTICLE AND THE BLOCKING AGENT
#324Antisense RNA for treating cancer and inhibition of metastasis and vectors for antisense sequestration
#325Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
#326Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#327Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-alpha
#328METHODS OF TREATING FGFR3 RELATED CONDITIONS
#329Activated HER3 as a marker for predicting therapeutic efficacy
#330Method of distinguishing mesenchymal stem cells
#331DRG11-RESPONSIVE (DRAGON) GENE FAMILY
#332Modular point-of-care devices, systems, and uses thereof
#333Detection of protein to protein interactions
#334Fusion proteins and methods thereof
#335METHOD FOR PREDICTING THE RESPONSE TO HER2-DIRECTED THERAPY
#336Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
#337mAB 2 anti-Met antibody
#338Isoform specific anti-HER4 antibodies
#339Methods of determining patient response by measurement of HER-3 and P95
#340SYSTEMS AND METHODS FOR FACILITATING DIAGNOSIS, PROGNOSIS AND TREATMENT OF CANCER BASED ON DETECTION OF HER3 ACTIVATION
#341Drug selection for non-small cell lung cancer therapy
#342Method of reducing blood glucose by administering RON agonists
#343Compositions and methods for growth factor modulation
#344Pre-eclampsia biomarkers
#345METHODS OF PREDICTING RESPONSIVENESS OF A CANCER TO AN AGENT AND METHODS OF DETERMINING A PROGNOSIS FOR A CANCER PATIENT
#346Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
#347METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MAMMALS HAVING LUNG ADENOCARCINOMA CHARACTERIZED BY NEUROENDOCRINE DIFFERENTIATION
#348Method for treating muscle-invasive bladder cancer, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients
#349Non-Antagonistic EGFR-Binding Molecules and Immunoconjugates Thereof
#350Anti-FGFR2 antibodies and pharmaceutical compositions thereof
#351METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
#352Methods for determining prognosis of colorectal cancer
#353Process for detection and optional quantification of an analyte
#354Modular point-of-care devices, systems, and uses thereof
#355Modular point-of-care devices, systems, and uses thereof
#356Methods of producing antibodies specific for p95
#357HER3 protein SRM/MRM assay
#358Capture and release of particles from liquid samples
#359METHOD OF DETECTING C-MET GENE AMPLIFICATION CELL
#360Compositions and methods for growth factor modulation
#361Compositions and methods for growth factor modulation
#362Cell-Based Assay for Neutralizing Antibodies
#363Modular point-of-care devices, systems, and uses thereof
#364Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#365Means and methods applying sFlt-1/PlGF or endoglin/PlGF ratio to rule out onset of preeclampsia within a certain time period
#366Compositions and methods for growth factor modulation
#367EGFR-binding peptide
#368METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHODS
#369DEVICES AND METHODS FOR ENRICHMENT AND ALTERATION OF CIRCULATING TUMOR CELLS AND OTHER PARTICLES
#370RELEASABLE MAGNETIC CELL CAPTURE SYSTEM
#371Diagnostic Markers of Indolent Prostate Cancer
#372Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
#373Fully human antibodies and fragments recognizing human c-Met
#374METHODS FOR CLASSIFYING TUMORS AND USES THEREFOR
#375METHODS OF PROGNOSTICATING AND TREATING CANCER
#376Markers for preeclampsia
#377Isolated cardiac stem cells and methods of their use
#378PRE-SELECTION OF SUBJECTS FOR THERAPEUTIC TREATMENT WITH AN HSP90 INHIBITOR BASED ON HYPOXIC STATUS
#379HER3 binding polypeptides
#380Human domain antibodies against components of the human insulin-like growth factor (IGF) system
#381Antibodies that specifically bind to DRG11-responsive (DRAGON) proteins
#382METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION USING RARE CELLS
#383Combination treatment of cancer
#384METHOD FOR THE SELECTION AND PRODUCTION OF TAILOR-MADE, SELECTIVE AND MULTI-SPECIFIC THERAPEUTIC MOLECULES COMPRISING AT LEAST TWO DIFFERENT TARGETING ENTITIES AND USES THEREOF
#385EPITOPES OF EPIDERMAL GROWTH FACTOR RECEPTOR SURFACE ANTIGEN AND USE THEREOF
#386DETECTING AND SORTING CELLS OR PARTICLES
#387NANOVECTOR BASED DRUG DELIVERY SYSTEM FOR OVERCOMING DRUG RESISTANCE
#388Methods of generating mesenchymal stem cells which secrete neurotrophic factors
#389Cancer biomarkers and methods of use thereof
#390THERANOSTIC METHOD BASED ON THE DETECTION OF HER2-HER2 DIMERS
#391Modular point-of-care devices, systems, and uses thereof
#392BIOMARKERS AND METHODS FOR DETERMINING EFFICACY OF ANTI-EGFR ANTIBODIES IN CANCER THERAPY
#393EGFR AND KRAS MUTATIONS
#394Fibroblast growth factor receptors as diagnostic markers of acquired sensory neuronopathies
#395CIRCULATING TUMOR CELL ASSAY
#396Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-EGFR drug
#397Fluorescent marker for tissue staining containing phosphor-containing nanoparticle and method using same
#398CANCER PROGNOSTIC ASSAYS
#399SPARC and methods of use thereof
#400KLOTHO BETA
#401Anti-FGFR2 antibodies and methods of use thereof for treating cancer
#402Method for predicting the response to HER2-directed therapy
#403METHOD FOR THE DIAGNOSIS OF MAMMALS
#404Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#405Anti-c-met antibodies
#406MARKER QUANTITATION IN SINGLE CELLS IN TISSUE SECTIONS
#407Aptamers and diagnostic methods for detecting the EGF receptor
#408Methods and Compositions for Treatment of Chlamydial Infection and Related Diseases and Disorders
#409Devices and methods of cell capture and analysis
#410Antibodies that specifically bind to DRG11-responsive (dragon) proteins
#411Methods of selecting epidermal growth factor receptor (EGFr) binding agents
#412Cell-surface signatures for isolating neurons from cell cultures derived from pluripotent stem cells
#413Curaxins for use in treating carcinogen-induced cancer
#414Method of enhancing the efficacy of anti-hepatocyte growth factor receptor breast cancer therapy by administering an inhibitor of mena
#415Method of blocking vascular leakage using an anti-ANG2 antibody
#416Anti-Ang2 antibody
#417Recurrent gene fusions in cancer
#418Methods of detecting tumor cells
#419Methods, kits, and systems for treatment of metastatic papillary thyroid cancer
#420MSC surface marker
#421Aptamer which selectively binds to ERBB2 receptor and uses thereof
#422Sample processing device with detachable slide
#423Determination of sFlt-1:angiogenic factor complex
#424System and method for determining individualized medical intervention for a disease state
#425System and method for determining individualized medical intervention for a disease state
#426Modular point-of-care devices, systems, and uses thereof
#427Aptamers and diagnostic methods for detecting the EGF receptor
#428Antibody-endostatin fusion protein and its variants
#429SRM/MRM assay for the receptor tyrosine-protein kinase erbB-4 protein (HER4)
#430Use of VEGFR1 as a biomarker
#431Use of neuregulin-4 for treatment of inflammatory bowel disease and necrotizing enterocolitis
#432Mutations in the epidermal growth factor receptor gene
#433Antibodies to insulin-like growth factor I receptor
#434Biomarkers of immunotherapy efficacy
#435EGFR mutations
#436Biomarkers to identify patients that will respond to treatment and treating such patients
#437Detection of targets using magnetic resonance
#438cMET protein SRM/MRM assay
#439Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
#440Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
#441Truncated HER2 SRM/MRM assay
#442Oral cancer point of care diagnostics
#443Her3 protein SRM/MRM assay
#444Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
#445Modular point-of-care devices, systems, and uses thereof
#446Method of detecting a urine protein fragment and a serum protein fragment
#447Covalently dimerized bivalent binding agents
#448Methods of determining chondrocytes
#449EGFR-related polypeptides and methods of use
#450Bispecific single chain Fv antibody molecules and methods of use therof
#451Growth factor isoform
#452Tissue staining method with staining agent containing particle holding plural phosphors
#453Volatile organic compounds for detecting cell dysplasia and genetic alterations associated with lung cancer
#454Methods and use of compounds that bind to HER2/neu receptor complex
#455Method for predicting breast cancer patient response to combination therapy
#456Method of identifying transmembrane protein-interacting compounds
#457HER-3 antibodies and methods of use
#458Method of treating colorectal cancer tumor
#459Reduction of TGF beta signaling in myeloid cells in the treatment of cancer
#460Epidermal growth factor receptor variants and pharmaceutical compositions thereof
#461Methods for predicting response of triple-negative breast cancer to therapy
#462Epidermal Growth Factor Receptor (EGFR) Protein SRM Assay
#463METHOD OF IDENTIFICATION OF CELLS THAT SHOW SENSITIVITY TO MODULATION OF SIGNALING MEDIATED BY A FIBROBLAST GROWTH FACTOR RECEPTOR OR A VARIANT THEREOF
#464Methods for measuring the level of insulin-like growth factor 1 receptor (IGF1R) protein using SRM/MRM assay
#465Endoglin antibodies
#466ANTIBODY SPECIFIC TO ACTIVATED EGFR
#467Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
#468SIMULTANEOUS DETECTION OF MUTATIONAL STATUS AND GENE COPY NUMBER
#469ADMINISTERING ANTI-PLACENTAL GROWTH FACTOR ANTIBODIES
#470OBJECTIVE, QUANTITATIVE METHOD TO PREDICT HISTOLOGICAL SUBTYPE IN NON-SMALL CELL LUNG CANCER
#471Compositions And Methods For Cell Based Retinal Therapies
#472PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF
#473PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF
#474PROTEIN MARKERS FOR DETECTING LIVER CANCER AND METHOD FOR IDENTIFYING THE MARKERS THEREOF
#475METHODS OF PROGNOSIS AND DIAGNOSIS IN CHRONIC HEART FAILURE
#476METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2
#477NT-pro ANP and SFlt-1 for the differentiation between circulatory and ischemic events
#478DRG11-responsive (dragon) polypeptides
#479DRG11-responsive (DRAGON) gene family
#480Human domain antibodies against components of the human insulin-like growth factor (IGF) system
#481BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO EPIDERMAL GROWTH FACTOR RECEPTOR MODULATORS
#482GENERATION, CHARACTERIZATION AND USES THEREOF OF ANTI-HER3 ANTIBODIES
#483Method for predicting breast cancer patient response to endocrine therapy
#484DRG11-responsive (DRAGON) gene family
#485Modular point-of-care devices, systems, and uses thereof
#486WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#487MER DIAGNOSTIC AND THERAPEUTIC AGENTS
#488Monoclonal antibodies to fibroblast growth factor receptor 2
#489Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
#490ANTI-ESTROGEN AND IMMUNE MODULATOR COMBINATIONS FOR TREATING BREAST CANCER
#491COMPOSITIONS AND METHODS FOR DEMONSTRATING SECRETORY IMMUNE SYSTEM REGULATION OF STEROID HORMONE RESPONSIVE CANCER CELL GROWTH
#492Methods for assessing and identifying or evolving conditionally active therapeutic proteins
#493Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
#494Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
#495Devices and methods of cell capture and analysis
#496Biomarker and Method for Predicting Sensitivity to MET Inhibitors
#497BIOMARKERS AND METHODS FOR DETERMINING EFFICACY OF ANTI-EGFR ANTIBODIES IN CANCER THERAPY
#498Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
#499FCgamma POLYMORPHISMS FOR PREDICTING DISEASE AND TREATMENT OUTCOME
#500METHODS TO DIAGNOSE A REQUIRED REGULATION OF TROPHOBLAST INVASION
#501Imaging probes, methods of making imaging probes, and methods of imaging
#502Diagnosis of preeclampsia
#503BREAST CANCER ERADICATION PROGRAM
#504Receptor gene screening for detecting or diagnosing cancer
#505OPTIMIZING ERYTHROPOIETIN THERAPY
#506ErbB3 ANTIBODIES
#507Protein markers for detecting liver cancer and method for identifying the markers thereof
#508Antibodies to insulin-like growth factor I receptor
#509WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#510DEVICES AND METHODS FOR ENRICHMENT AND ALTERATION OF CIRCULATING TUMOR CELLS AND OTHER PARTICLES
#511ISOFORM SPECIFIC ANTI-HER4 ANTIBODIES
#512Detection of Activation of Endothelial Cells as Surrogate Marker for Angiogenesis
#513Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
#514EGFR mutations
#515USE OF S-ERBB-3 AS A MARKER FOR CANCER
#516Dual Variable Domain Immunnoglobulins and Uses Thereof
#517Markers for Assessing the Susceptibility of Cancer to IGF-1R Treatment
#518IDENTIFICATION OF SIGNATURE GENES ASSOCIATED WITH HEPATOCELLULAR CARCINOMA
#519METHODS FOR IDENTIFYING ERBB2 ALTERATION IN TUMORS
#520METHODS OF DIAGNOSING AND TREATING COMPLICATIONS OF PREGNANCY
#521EGFR mutations
#522DIAGNOSTIC SUBSTANCE FOR USE IN A METHOD FOR DETERMINING THE AGGRESSIVENESS OF A PROSTATE TUMOR AND DIAGNOSTIC METHOD
#523Compositions and methods for modulating skin pigmentation
#524Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-alpha
#525Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors
#526Phosphorylated C-ErbB2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
#527Methods to identify responsive patients
#528Screening assay employing Dex and GDF8
#529Methods for Treating Cancers Comprising K-ras Mutations
#530Molecular affinity clamp technology and uses thereof
#531ASSESSING AND TREATING BREAST CANCER PATIENTS
#532Method of determination of receptor binding saturation effected by monoclonal antibodies
#533Method for predicting the response to HER2-directed therapy
#534SERUM PROTEOMIC FOR FINDING DIAGNOSTIC MARKERS AND FOR MONITORING THERAPEUTICAL INTERVENTION IN TREATMENT OF HEPATOCELLULAR CARCINOMA
#535METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR CANCER
#536COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CANCER
#537Methods for Identifying Tumors That are Responsive to Treatement With Anti-ErbB2 Antibodies
#538Methods and apparatus for conducting multiple measurements on a sample
#539Modulation of growth hormone receptor expression and insulin-like growth factor expression
#540COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PANCREATIC CANCER
#541SCREENING METHOD FOR PREDICTING SUSCEPTIBILITY TO BREAST CANCER
#542URINE AND SERUM BIOMARKERS ASSOCIATED WITH DIABETIC NEPHROPATHY
#543VASCULAR MARKERS IN THE REMODELING OF CARDIAC INJURY
#544EGFR AND KRAS MUTATIONS
#545Urine and serum biomarkers associated with diabetic nephropathy
#546Endoglin antibodies
#547Determining an expression status of human epidermal growth factor receptor 2 (HER2) in a biological sample
#548COMPOSITIONS AND METHODS FOR INHIBITING ANGIOGENESIS AND TUMORIGENESIS
#549METHODS OF MONITORING THE MODULATION OF THE KINASE ACTIVITY OF FIBROBLAST GROWTH FACTOR RECEPTOR AND USES OF SAID METHOD
#550Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
#551HER3 AS A DETERMINANT FOR THE PROGNOSIS OF MELANOMA
#552ANTI-ErbB2 ANTIBODIES
#553MN/CA IX and EGFR Pathway Inhibition
#554Methods for treating cancer using ephrin type-A receptor 10 antibodies conjugated to cytotoxic agents
#555Polypeptide ESDN, polynucleotides encoding the polypeptide, and utility of the polypeptide
#556Treatment of Cancers Expressing p95 ErbB2
#557Method for the administration of anti-cancer drugs
#558Screening method for predicting susceptibility to breast cancer
#559METHOD FOR DETECTING TRUNCATED MOLECULES
#560BIOMARKERS FOR IGF-1R INHIBITOR THERAPY
#561Growth factor isoform
#562Anti-estrogen and immune modulator combinations for treating breast cancer
#563EGFR mutations
#564Polypeptides and methods of use
#565Method for diagnosing an increased risk of preeclampsia by measuring the level of HIF-α
#566METHOD OF IDENTIFYING DIAGNOSTIC REAGENTS
#567Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein
#568Human Cancer Stem Cell Culture Compositions Comprising ErbB2 Variants and Methods of Use
#569Method of identifying transmembrane protein-interacting compounds
#570AGENTS AND METHODS FOR MODULATING MACROPHAGE INHIBITORY CYTOKINE (MIC-1) ACTIVITY
#571Breast cancer eradication program
#572WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
#573Antibodies to insulin-like growth factor I receptor
#574Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
#575Methods of Determining Patient Response By Measurement of HER-2 Expression
#576DEVICES AND METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION BY ENRICHING RARE CELLS
#577METHODS FOR DIAGNOSING, PROGNOSING, OR THERANOSING A CONDITION USING RARE CELLS
#578Diagnosis of preeclampsia
#579Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
#580Method of screening endothelial cells for angiogenic capability
#581NOVEL PROTEINS WITH TARGETED BINDING
#582IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
#583Methods of determining patient response by measurement of Her-3
#584Protein scaffolds and uses thereof
#585Urine and serum biomarkers associated with diabetic nephropathy
#586Monoclonal antibodies to fibroblast growth factor receptor 2
#587METHODS FOR DIAGNOSING BIOLOGICAL SAMPLES CONTAINING STEM CELLS
#588Methods of identifying agents that modulate methylation of VEGFR1 by SMYD3
#589METHODS AND USES RELATED TO RHBDL4
#590METHODS AND COMPOSITIONS FOR DETERMINING THE EFFICACY OF BREAST CANCER THERAPEUTICS
#591RECEPTOR FAMILY PROFILING
#592KLOTHO BETA
#593PREVENTIVE OR REMEDY FOR ER-NEGATIVE AND HER2-NEGATIVE BREAST CANCER AND METHOD OF SCREENING THE SAME
#594Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
#595METHOD FOR INHIBITING SIGNALING MEDIATED BY ErbB2, SIGNALING INHIBITOR TO BE USED THEREFOR AND USE THEREOF
#596Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
#597Methods for detecting diabetic nephropathy comprising measuring the expression of Smad1
#598DETECTION OF ELEVATED LEVELS OF HER-2/NEU PROTEIN FROM NON-ISOLATED CIRCULATING CANCER CELLS AND TREATMENT
#599Tissue analysis and kits therefor
#600COMPOSITIONS AND METHODS FOR TREATING CANCER BY MODULATING HER-2 AND EGF RECEPTORS